Correction: CDK4/ 6 inhibition provides a potent adjunct to Her2- targeted therapies in preclinical breast cancer models
Agnieszka K. Witkiewicz, Derek Cox, Erik S. Knudsen
Abstract
[This corrects the article DOI: 10.18632/genesandcancer.24.].
Topics & Concepts
MedicinePalbociclibCancer researchTargeted therapyCyclin D1Breast cancerPharmacologyKinaseOncologyCancerCell cycleInternal medicineMetastatic breast cancerBiologyCell biologyHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia Research